Table VII.
Baseline characteristics of REGARDS participants whose preserved eGFRcr was confirmed versus not confirmed using eGFRcys stratified by age
| Parameter | < 65 years | 65 to 79 years | ≥ 80 years | |||
|---|---|---|---|---|---|---|
| Preserved eGFRcr not confirmed using eGFRcys | Preserved eGFRcr confirmed using eGFRcys | Preserved eGFRcr not confirmed using eGFRcys | Preserved eGFRcr confirmed using eGFRcys | Preserved eGFRcr not confirmed using eGFRcys | Preserved eGFRcr confirmed using eGFRcys | |
| Number of participants (%)a | 847 (6.3) | 12,534 (93.7) | 1,899 (19.3) | 7,930 (80.7) | 572 (45.4) | 687 (54.6) |
| Age, mean (SD) [years] | 59.2 (4.0) | 57.0 (5.0) | 72.0 (4.1) | 70.3 (4.0) | 83.2 (3.0) | 82.7 (2.7) |
| Men, n (%) | 259 (30.6) | 5,481 (43.7) | 769 (40.5) | 4,002 (50.5) | 269 (47.0) | 365 (53.1) |
| Black, n (%) | 378 (44.6) | 5,327 (42.5) | 646 (34.0) | 3,067 (38.7) | 167 (29.2) | 252 (36.7) |
| Region of residence, n (%): | ||||||
| Stroke belt (buckle states) | 200 (23.6) | 2,701 (21.5) | 420 (22.1) | 1,559 (19.7) | 99 (17.3) | 123 (17.9) |
| Stroke belt (non-buckle states) | 314 (37.1) | 4,540 (36.2) | 658 (34.7) | 2,690 (33.9) | 169 (29.6) | 212 (30.9) |
| Other contiguous US states | 333 (39.3) | 5,293 (42.2) | 821 (43.2) | 3,681 (46.4) | 304 (53.1) | 352 (51.2) |
| Less than high school, n (%) | 119 (14.1) | 980 (7.8) | 344 (18.1) | 1,118 (14.1) | 98 (17.2) | 126 (18.4) |
| No physical activity, n (%) | 382 (45.9) | 3,712 (30.0) | 831 (44.5) | 2,368 (30.4) | 268 (47.8) | 262 (39.0) |
| Current smoking, n (%) | 248 (29.4) | 2,266 (18.2) | 279 (14.8) | 803 (10.2) | 29 (5.1) | 16 (2.4) |
| History of CHD, n (%) | 187 (22.6) | 1,312 (10.7) | 532 (28.5) | 1,472 (18.9) | 175 (31.3) | 161 (24.0) |
| History of stroke, n (%) | 72 (8.5) | 485 (3.9) | 192 (10.2) | 440 (5.6) | 52 (9.2) | 58 (8.5) |
| Diabetes, n (%) | 277 (32.9) | 2,145 (17.2) | 534 (28.3) | 1,542 (19.6) | 108 (19.0) | 92 (13.4) |
| High waist circumference, n (%) | 623 (74.3) | 5,924 (47.5) | 1,157 (61.3) | 3,462 (43.9) | 223 (39.3) | 231 (33.8) |
| Body mass index, n (%) [kg/m2]: | ||||||
| < 18.5 | 6 (0.7) | 113 (0.9) | 23 (1.2) | 83 (1.1) | 7 (1.2) | 13 (1.9) |
| 18.5 to < 25.0 | 84 (10.3) | 2,725 (21.9) | 360 (19.1) | 2,152 (27.2) | 210 (37.0) | 282 (41.3) |
| 25.0 to < 30.0 | 201 (24.5) | 4,444 (35.6) | 636 (33.7) | 3,263 (41.3) | 233 (41.0) | 289 (42.3) |
| ≥ 30.0 | 528 (64.5) | 5,183 (41.6) | 866 (46.0) | 2,405 (30.4) | 118 (20.8) | 99 (14.5) |
| Taking statins, n (%) | 268 (31.6) | 3,100 (24.7) | 710 (37.4) | 2,820 (35.6) | 175 (30.6) | 204 (29.7) |
CHD – coronary heart disease, eGFR – estimated glomerular filtration rate, REGARDS – REasons for Geographic And Racial Differences in Stroke, SD – standard deviation, US – United States.
a
Percentage within age group. Preserved eGFRcr confirmed using eGFRcys was defined as eGFRcr and eGFRcys ≥ 60 ml/min/1.73 m2. Preserved eGFRcr not confirmed using eGFRcys was defined as eGFRcr ≥ 60 ml/min/1.73 m2 and eGFRcys < 60 ml/min/1.73 m2. Equations for eGFRcr and eGFRcys are shown in Table I.